LABORATORIOS FARMACEUTICOS ROVI, S.A. «12345» Page 5 out of 5 22/06/2021 18:29 LABORATORIOS FARMACEUTICOS ROVI, S.A. (LABORATORIOS ROVI) On significant placements in financial instruments Bestinver announces the beginning of an acceralted book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Register number: 947 29/04/2021 07:05 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company announces that it increases its fill-finish capacity for the COVID-19 Vaccine Moderna Register number: 858 12/04/2021 08:35 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company publishes the press release concerning the extension of the collaboration that currently exists between ROVI and Moderna for the manufacture of the active substance of the COVID-19 Vaccine Moderna. Register number: 837 02/03/2021 08:10 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States Register number: 782 02/03/2021 08:06 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States. Register number: 781 24/02/2021 08:03 LABORATORIOS FARMACEUTICOS ROVI, S.A. On corporate governance La Sociedad informa sobre los acuerdos adoptados por su Consejo de Administración. Register number: 745 27/11/2020 08:20 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company releases the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Register number: 610 09/07/2020 13:56 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company informs on the collaboration with Moderna for outside the United States fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate Register number: 322 Page 5 out of 5 «12345»
